ACE2 and COVID-19: For instance, as we reported previously, ACE2 is critical to inactivate des-Arg9-bradykinin and deficiency of pulmonary ACE2, which has been proposed in COVID-19 patients, could lead to pulmonary angioedema and exacerbated lung inflammation.